Difference between revisions of "Example orders for Docetaxel (Taxotere) in non-small cell lung cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "cycles, given until progression of disease or unacceptable toxicity" to "cycles")
m (Text replacement - "'''Use of this site is subject to you reading and agreeing with the terms set forth" to "{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | <span style="font-family:Arial; font-size:200%"> Hello!<br>  We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br>  Please help us by filling it out!<br>  '''Link:''' http://j.mp/2BlBaoQ </span> |}<br>'''Use of this site is subject to you reading and agreeing with the terms set forth")
Line 1: Line 1:
'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''   
+
{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center"
 +
|
 +
<span style="font-family:Arial; font-size:200%">&nbsp;Hello!<br>
 +
&nbsp;We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br>
 +
&nbsp;Please help us by filling it out!<br>
 +
&nbsp;'''Link:''' http://j.mp/2BlBaoQ
 +
</span>
 +
|}<br>'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''   
  
 
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
 
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.

Revision as of 21:04, 30 December 2017

 Hello!
 We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.
 Please help us by filling it out!
 Link: http://j.mp/2BlBaoQ


Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.

Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.


Docetaxel (Taxotere)

Original references may be found at Docetaxel (Taxotere)

Example regimen #1

  • Docetaxel (Taxotere) 75 mg/m2 IV on day 1
    • Administer over 30-60 minutes. Use non-DEHP tubing/paclitaxel tubing.

21-day cycles

Supportive medications

  • Prochlorperazine (Compazine) 10 mg PO x 1 prn nausea
  • Dexamethasone (Decadron) 8 mg PO BID the day before, day of, and day after chemotherapy

Hydration:

  • 500 ml NS at KVO rate. Use as running IV for chemotherapy infusion. Give up to 500 ml NS.

Monitoring:

  • On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr, alk phos, AST, ALT, total bilirubin, carcinoembryonic antigen
  • On cycle 1 day 10, check nadir CBC with differential, absolute neutrophil count (ANC). Need for further nadir count checks to be determined by degree of cytopenias.
  • Assess for response with CT scan every 3+ cycles depending on symptoms

Outpatient medications:

  • Dexamethasone (Decadron) as described above
  • Lorazepam (Ativan) 0.5 mg PO Q6H prn anxiety, insomnia, nausea
  • Ondansetron (Zofran) 4 mg PO Q6H prn nausea

Clinical scenario & comments:

  • 60 year-old lady with stage IV adenocarcinoma of the lung, s/p treatment with first-line therapy for metastatic disease with Carboplatin (Paraplatin) & Pemetrexed (Alimta), with good response. Progressed after maintenance therapy with Pemetrexed (Alimta).

Example regimen #2 - dose reduction & neulasta for pancytopenia

  • Docetaxel (Taxotere) 60 mg/m2 IV on day 1
    • Administer over 30-60 minutes. Use non-DEHP tubing/paclitaxel tubing.

21-day cycles

Supportive medications

Hydration:

  • 500 ml NS at KVO rate. Use as running IV for chemotherapy infusion. Give up to 500 ml NS.

Monitoring:

  • On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr, alk phos, AST, ALT, total bilirubin, carcinoembryonic antigen
  • Once on day 10-14, check nadir CBC with differential, absolute neutrophil count (ANC). Transfuse RBCs as needed.
  • Assess for response with CT scan every 3+ cycles depending on symptoms

Outpatient medications:

  • Dexamethasone (Decadron) as described above
  • Lorazepam (Ativan) 0.5 mg PO Q6H prn anxiety, insomnia, nausea
  • Ondansetron (Zofran) 4 mg PO Q6H prn nausea

Clinical scenario & comments:

  • 72 year-old lady with stage IV adenocarcinoma of the lung with bony metastases and history of pathologic fracture, s/p treatment with first-line therapy for metastatic disease with Carboplatin (Paraplatin) & Pemetrexed (Alimta), who initially responded but them progressed on CT imaging after cycle 5 of therapy. Cycle 1 of therapy was given as above in example #1, but due to significant neutropenia, anemia, and thrombocytopenia (50-60) at nadir blood count, Docetaxel (Taxotere) was dose reduced as above, and Pegfilgrastim (Neulasta) added. In later cycles, neutropenia was not an issue, RBC transfusion need was minimal, and platelet counts were adequate for treatment.